Source: CureToday articles
The biologics license application seeks potential approval of a Darzalex Faspro-based regimen for newly diagnosed multiple myeloma ineligible for transplant.
Recent Content
- Ninlaro Combo Delays Post-Transplant Progression in Relapsed Myeloma
- Deep hematologic response to RD treatment in patients with multiple myeloma is associated with overexpression of IL-17R in CD138+ plasma cells
- Aurigene Oncology Limited announces promising results of Phase 1 study for India’s first trial for novel autologous CAR-T cell therapy for multiple myeloma
- Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)
- Imaging aspects of maxillomandibular bone alterations in patients with multiple myeloma treated with bisphosphonates: A systematic review
- Outcomes in Randomized Controlled Trials of Therapeutic Interventions for Multiple Myeloma: a Systematic Review
- Transplant in myeloma: individualized approaches needed depending on context, access and biology
- FDA Receives Application to Review D-VRd in Multiple Myeloma Subset
- Impact of daratumumab on collection and engraftment in multiple myeloma patients undergoing hematopoietic stem cell mobilization with G-CSF plus on-demand plerixafor
- Understanding Multiple Myeloma Symptoms